740 related articles for article (PubMed ID: 16798651)
21. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
22. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Kuo HT; Peng CT; Tsai MY
Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
[TBL] [Abstract][Full Text] [Related]
23. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
24. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
[TBL] [Abstract][Full Text] [Related]
25. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
26. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
27. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
28. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
29. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Huang YC; Chang JS; Wu KH; Peng CT
Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
31. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
[TBL] [Abstract][Full Text] [Related]
32. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
33. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Wu KH; Chang JG; Ho YJ; Wu SF; Peng CT
Hemoglobin; 2006; 30(2):251-6. PubMed ID: 16798650
[TBL] [Abstract][Full Text] [Related]
34. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
35. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
37. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
38. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
39. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
40. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
